Trident Lifeline Limited

BSE:543616 Stock Report

Market Cap: ₹3.2b

Trident Lifeline Valuation

Is 543616 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 543616 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 543616's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 543616's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 543616?

Key metric: As 543616 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 543616. This is calculated by dividing 543616's market cap by their current earnings.
What is 543616's PE Ratio?
PE Ratio32.6x
Earnings₹97.09m
Market Cap₹3.17b

Price to Earnings Ratio vs Peers

How does 543616's PE Ratio compare to its peers?

The above table shows the PE ratio for 543616 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.1x
531569 Sanjivani Paranteral
48.9xn/a₹3.4b
PAR Par Drugs and Chemicals
19.8xn/a₹3.6b
SMSLIFE SMS Lifesciences India
13.9xn/a₹3.0b
539730 Fredun Pharmaceuticals
17.9xn/a₹3.2b
543616 Trident Lifeline
32.6xn/a₹3.2b

Price-To-Earnings vs Peers: 543616 is expensive based on its Price-To-Earnings Ratio (32.6x) compared to the peer average (25.1x).

Price to Earnings Ratio vs Industry

How does 543616's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$70.43m
524652 Ind-Swift
2xn/aUS$13.12m
No more companies available in this PE range
543616 32.6xIndustry Avg. 31.7xNo. of Companies18PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 543616 is expensive based on its Price-To-Earnings Ratio (32.6x) compared to the Indian Pharmaceuticals industry average (31.6x).

Price to Earnings Ratio vs Fair Ratio

What is 543616's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

543616 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio32.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 543616's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vilin Bio Med

₹293.6m

Engages in the manufacture and sale of pharmaceutical products in India.

VILINBIO

₹21.05

7D

7.4%

1Y

-0.9%

Venus Remedies

₹3.9b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹291.85

7D

-3.6%

1Y

-22.2%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹928.00

7D

-1.7%

1Y

15.6%